Transforming

Women’s Reproductive Health with Early Cancer Detection

Millions of women globally suffer in silence
with Polycystic Ovarian
Syndrome (PCOS), Endometriosis,
and Human Papillomavirus
(HPV)
infections.

Endometriosis Endometriosis
PCOS PCOS
HPV HPV infections
Another

These conditions increases their risk of developing Cervical, Endometrial and Ovarian cancers by 4 times.

Precimmo helps you take control with early, non-invasive screening
—because early detection means safer treatment”

Aura-C

Cervical Cancer Early Detection

Cervical Cancer Early Detection

PAX1 And JAM3 Dual-Gene Methylation Technology

A Gentle, Non-Invasive Test That Screens For Cervical Cancer Using Exfoliated Cells— No Pain, No Hassle

Aura-E

Endometrial Cancer Early Detection

Endometrial Cancer Early Detection

CDO1 and CELF4 Dual-Gene Methylation Technology

A Simple Self-Collected Swab Helps Detect Early Signs Of Endometrial Cancer— Quick, Safe, And Accurate

Aura-O

Ovarian Cancer Early Detection

Ovarian Cancer Early Detection

CDO1 and HOXA9 Dual-Gene Methylation Technology

Detects Ovarian Cancer Early with Just A Routine Blood Sample— No Invasive Procedures Needed

Clinically tested in

30,000

Women

Non-invasive

Self-collection

Procedure

Approved in

35

Countries

Personalised Cancer Care with

Precision Immuno-Oncology

By decoding your genetics, immune profile,
and tumor biology, Precimmo understands
your cancer at its molecular core—delivering
clinical insights needed to guide the most
effective treatment with unmatched
precision.

”Because you are unique—and the right
therapy begins with the right diagnosis”

Discover Precimmo Dx

OncoAdvisor™ 

Your AI Companion in Precision Oncology

Combining multi-omics intelligence with
clinical insights to deliver personalised
therapy
recommendations for every cancer
patient
—before it’s too late.

Learn More